DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Treatment of Hypertension With Adalat® in Combination With Other Drugs

Information source: Bayer
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension

Intervention: Nifedipine (Adalat, BAYA1040) (Drug)

Phase: N/A

Status: Completed

Sponsored by: Bayer

Official(s) and/or principal investigator(s):
Bayer Study Director, Study Director, Affiliation: Bayer

Summary

To investigate the therapeutic effectiveness of long acting nifedipine containing combination therapy in the treatment of hypertensive patients.

Clinical Details

Official title: AdADOSE - Antihypertensive Treatment With Adalat® in Different Doses and Combination Therapy

Study design: Observational Model: Cohort, Time Perspective: Prospective

Primary outcome: Evaluation of treatment success (lowering of blood pressure in mmHg) in adult hypertensive patients

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Previously untreated hypertensive patients starting with combination therapy

containing nifedipine or

- Insufficiently controlled hypertensive pts. receiving nifedipine as an add-on to

existing non-CCB (calcium-channel-blocker) containing antihypertensive therapy Exclusion Criteria:

- None. Exclusion criteria are defined by contraindications and precautions as stated

in the local product information.

Locations and Contacts

Many Locations, Bahrain

Many Locations, Egypt

Many Locations, Jordan

Many Locations, Lebanon

Many Locations, Morocco

Many Locations, Oman

Many Locations, Pakistan

Many Locations, Qatar

Many Locations, Russian Federation

Many Locations, Saudi Arabia

Many Locations, United Arab Emirates

Additional Information

Click here and search for drug information provided by the FDA.

Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.

Starting date: January 2010
Last updated: June 26, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017